B lymphocytes differentiate into antibody-secreting cells under the antigen-specific control of follicular helper T cells (T FH cells). Here we demonstrate that isotype-switched plasma cells expressed major histocompatibility complex (MHC) class II, the costimulatory molecules CD80 and CD86, and the intracellular machinery required for antigen presentation. Antigen-specific plasma cells accessed, processed and presented sufficient antigen in vivo to induce multiple helper T cell functions. Notably, antigen-primed plasma cells failed to induce interleukin 21 (IL-21) or the transcriptional repressor Bcl-6 in naive helper T cells and actively decreased these key molecules in antigen-activated T FH cells. Mice lacking plasma cells showed altered T FH cell activity, which provided evidence of this negative feedback loop. Hence, antigen presentation by plasma cells defines a previously unknown layer of cognate regulation that limits the antigen-specific T FH cell program that controls ongoing B cell immunity.
A r t i c l e s Vaccination with protein induces high-affinity memory B cells and persistent circulating antigen-specific antibodies for long-lasting humoral immunity 1, 2 . Follicular helper T cells (T FH cells) have emerged as another class of immunoregulatory cells [3] [4] [5] specialized to control the stepwise development of antigen-specific B cell immunity. In the first week after priming, antigen-specific T FH cells emerge [6] [7] [8] to initiate antibody secretion, isotype switching and the germinal center (GC) reaction 9 . In the GC, T FH cells regulate the development of high-affinity memory B cells [10] [11] [12] and the production of long-lived plasma cells 13 . After rechallenge with antigen, memory T FH cells promote the population expansion of antigen-specific memory B cells and the rapid induction of high-affinity plasma cells 7, 14 . Thus, antigen-specific T FH cell function is central to multiple facets of B cell immunity, but how this cognate regulatory activity is controlled remains poorly understood.
The development and function of antigen-specific T FH cells emerges progressively with separable requirements for cognate control. The initial programming of T FH cells occurs after the first contact with dendritic cells (DCs) expressing complexes of peptide and major histocompatibility complex (MHC) class II (pMHCII) in the T cell zones of draining lymphoid tissue 15 . Loss of the chemokine receptor CCR7 and expression of the chemokine receptor CXCR5 relocates T FH cells to B cell zones 6 and facilitates contact with antigen-primed pMHCII-expressing B cells [16] [17] [18] . The transcriptional repressor Bcl-6 (A000369) is expressed by the early pre-GC T FH cells 8 and is sufficient and necessary to induce this program in vivo [19] [20] [21] . Intercellular contact of long duration 17 with signals promoted by signaling lymphocyticactivation molecule receptors 17 and engagement of inducible costimulator (ICOS) through its ligand ICOSL on B cells is required for the entry of pre-GC T FH cells into the GC environment 22, 23 . Ectopic ICOS expression by naive helper T cells promotes excessive T FH population expansion, enlarged GCs and autoantibody production 9 . Interactions between interleukin 21 (IL-21; A001258) and its receptor IL-21R (A001259) are central to effective B cell immunity 24, 25 . Although T FH cells can develop in the absence of IL-21R (refs. 10, 11) , the lack of IL-21 signaling in B cells substantially compromises the GC reaction and the production of post-GC plasma cells [10] [11] [12] . The immunoregulatory receptor PD-1 expressed by T FH cells has also been linked to the control of GC B cell survival and post-GC plasma cell production mediated by the PD-1 ligand PD-L2 (ref. 13 ). Hence, clonal expansion and the cognate delivery of specific T FH cell functions also require a highly regulated program of progressive development in vivo.
Antibody-secreting cells constitute the critical effector B cell compartment produced through regulation by antigen-specific T FH cells in vivo. Plasma cells are defined as postmitotic antibody-secreting cells and represent the terminally differentiated component of the antibody-secreting cell compartment 1, 2 . Outside the GC, the development of plasma cells requires regulation by T FH cells and occurs rapidly during the first week after vaccination with proteins. These non-GC plasma cells do not somatically hypermutate 26, 27 but can switch antibody classes and typically have short half-lives of 3-5 d (ref. 28) . In contrast, the development of GC plasma cells involves affinity maturation and antibody class switching that results in long-lived compartments of high-affinity plasma cells 1, 2, 29 . The transcriptional repressor Blimp-1 (A003268) initiates the development of plasma cells in both pathways 30 , exerting its control largely through repression of Bcl-6 and the transcription factor Pax5 (ref. 31) , which allows derepression of the transcription factor XBP-1 (refs. 32, 33) . Moreover, IL-21, which is abundantly produced by T FH cells 8, [10] [11] [12] , potently induces Blimp-1 expression 34 and the development of plasma cells in a manner dependent on the transcription factors STAT3 and IRF4 (ref. 35 ). XBP-1 controls the response of unfolded proteins and supports many facets of the cellular secretory apparatus 32 . Lower surface expression of the B cell antigen receptor (BCR) and downregulation of the MHCII transactivator CIITA 36 suggest that plasma cells remain highly specialized for antibody secretion in vivo and have a lower capacity for immunoregulation and responsiveness.
Contrary to those expectations, we demonstrate here continued high expression of MHCII, the costimulatory molecules CD80 and CD86 and the intracellular machinery for antigen presentation in antigen-specific isotype-switched plasma cells in vivo. Notably, after being primed in vivo, antigen-specific plasma cells expressed pMHCII complexes and were able to activate antigen-specific helper T cells. Antigen-pulsed plasma cells induced the proliferation and differentiation of effector cells in vitro from naive antigen-specific helper T cells but promoted Blimp-1 in favor of the induction of Bcl-6 and IL-21. Furthermore, plasma cells shut down IL-21 production and decreased Bcl-6 expression in activated helper T cells in an antigen-specific manner. In support of the idea of that negative regulatory function, CXCR5 + PD-1 + T FH cells accumulated to large numbers in draining and distal lymphoid tissues after protein immunization of mice lacking B cell-expressed Blimp-1, which do not produce plasma cells in vivo. Large numbers of plasma cells seemed to be interspersed with helper T cells at the T cell-B cell borders and throughout the lymphoid tissue during the second week after antigen priming, with evidence of contact of helper T cells with plasma cells in situ. Finally, we diminished the expression of Bcl-6 and IL-21 in antigen-specific T FH cells in vivo through adoptive transfer of antigen-pulsed plasma cells. Our data demonstrate an antigen-presentation function for plasma cells during adaptive immunity that serves to limit ongoing antigenspecific T FH cell function. Hence, we propose an additional layer of negative regulation during adaptive immunity that is a functional sensor of plasma cell production that can refine the development of antigen-specific B cell memory.
RESULTS

Antigen-specific plasma cells express MHCII, CD80 and CD86
The antigen-specific B cell response to nitrophenylacetyl (NP) coupled to keyhole limpet hemocyanin (KLH) as a protein carrier is regulated by T FH cells and can be assessed directly by flow cytometry 14, 37 . After immunizing mice with NP-KLH, we were able to quantify antibodysecreting cells by intracellular labeling with antigen, the binding of antigen to the cell surface and secretion of antigen-specific antibodies by enzyme-linked immunospot assay ( Supplementary Fig. 1 ). Therefore, we were able to isolate antigen-specific antibody-secreting cells (immunoglobulin M negative (IgM − ) and CD138 + ) with distinct developmental histories for subsequent analysis of function ( Fig. 1a ). We found that by day 5 after secondary immunization with the Toll-like receptor 4 agonist-based Ribi adjuvant system, >90% of isotype-switched antibody-secreting cells did not incorporate the thymidine analog BrdU over the preceding 24 h in vivo ( Fig. 1b) . Thus, most antibody-secreting cells (specific and nonspecific) used in this study could be considered noncycling, terminally differentiated plasma cells.
In the antigen-specific compartment, IgM − CD138 + plasma cells had high surface expression of MHCII protein (Fig. 1c) . All recently formed plasma cells (non-GC at 7 d after initial priming; post-GC at 14 d after priming; and memory-response at 5 d after secondary challenge) had expression of MHCII equivalent to that of naive B cells and CD11c + DCs. Long-lived plasma cells that persisted in the spleen (>14 d after secondary challenge) or bone marrow (>14 d after secondary challenge; data not shown) had lower but readily demonstrable expression of MHCII. Isotype-switched plasma cells also upregulated expression of CD80 and CD86 and retained abundant expression at all developmental stages after antigen experience (Fig. 1d) . These data suggested that antigen-experienced plasma cells retained cognate intercellular interaction with pMHCII-specific helper T cells.
The same expression pattern for MHCII, CD80 and CD86 was evident in switched plasma cells regardless of antigen specificity and across different mouse strains ( Supplementary Fig. 2) . In contrast, many IgM + plasma cells had lost MHCII expression, with most also Fig. 3) . The switched plasma cell compartment had very low but detectable expression of mRNA encoding MHCII, its transactivator CIITA, and CD80 and CD86 ( Supplementary Fig. 4 ), as expected given the negative effect of Blimp-1 on CIITA during the development of plasma cells 36 . Thus, isotype-switched plasma cells express key surface proteins associated with MHCII-restricted antigen presentation even in the presence of low expression of mRNA encoding these proteins in vivo.
Plasma cells retain antigen-presentation machinery
Next we investigated the mechanism used by plasma cells to control MHCII-restricted antigen processing and presentation. We readily detected invariant chain protein (Ii; also called CD74) and complexes of the MHCII-associated Ii peptide CLIP and MHCII molecule I-A b intracellularly in antigen-specific IgM − CD138 + plasma cells in quantities similar to those in resting B cells ( Fig. 2a) .
We also found the peptide-editing complexes H-2M and H-2O by direct intracellular labeling for these proteins (Fig. 2b) . We detected CD74, H-2M and H-2O proteins at similar abundance in nonspecific switched MHCII hi and MHCII int plasma cells that represented recently formed and long-lived plasma cell compartments, respectively ( Supplementary Fig. 5 ). The abundance of mRNA encoding CD74, H-2M and H-2O was low but detectable in this switched plasma cell compartment ( Supplementary Fig. 5b-d) .
We found mRNA for the carboxypeptidases cathepsin B (CtsB) and CtsZ, associated with early endosomes, and the aminopeptidases AEP and CtsH, associated with lysosomes, in switched plasma cells ( Fig. 2c ). We also found mRNA for other cathepsin proteases (GILT, CtsS, CtsL, CtsC and CtsD), present in low abundance ( Supplementary Fig. 6 ). Therefore, in addition to evidence of cell surface MHCII, CD80 and CD86, there is abundant evidence of intracellular machinery involved in antigen processing and presentation in the specialized MHCII peptide-loading pathway in vivo.
Antigen-specific plasma cells present antigen in vivo
Although the machinery for antigen processing was in place, it remained important to address the ability of plasma cells to present specific antigenic peptides in vivo. Using hen egg lysozyme (HEL) as the immunogen, we directly visualized HEL-binding plasma cells in polyclonal B10.BR (H-2 k -restricted) mice 5 d after a secondary boost with soluble antigen (Fig. 3a) . Direct labeling with Aw3. 18 (ref. 38) , an antibody specific for the dominant helper T cell epitope of HEL amino acids 48-61 in I-A k , showed considerable specific pMHCII on HEL-binding plasma cells ( Fig. 3b) . There was negligible background antigen binding or expression of pMHCII in mice primed with irrelevant pigeon cytochrome c (PCC) antigen before the boost with soluble HEL (Fig. 3b) . Thus, antigen-specific memory-response plasma cells present detectable amounts of the dominant pMHCII 5 d after soluble protein rechallenge in vivo.
Plasma cells drive proliferation of specific helper T cells
At 10 d after primary adjuvant-driven immunization, most antigen-specific plasma cells express isotype-switched BCRs with point mutations and evidence of antigen-driven selection during the GC reaction 27 . To assess the ability of post-GC plasma cells to present antigen, we isolated IgM − CD138 + plasma cells 10 d after immunizing mice with PCC and cultured the cells together with naive PCCspecific helper T cells with transgenic expression of the 5C.C7 αβ T cell antigen receptor (TCR; Fig. 3c ). The switched plasma cells from PCC-immunized mice, but not those from control mice immunized with adjuvant only, promoted substantial proliferation of naive antigen-specific helper T cells without the addition of exogenous antigen. The addition of exogenous peptide promoted no further upregulation of the activation and memory marker CD44 or dilution of the cytosolic dye CFSE in vitro. Thus, antigen-specific post-GC plasma cells express sufficient pMHCII and provide adequate costimulation in vivo to drive the proliferation of naive antigen-specific helper T cells in vitro. Next, to assess whether plasma cells can activate naive helper T cells in vivo, we pulsed plasma cells with HEL amino acids 48-61 and adoptively transferred the cells into mice containing CFSE-labeled, HEL-specific, naive helper T cells with transgenic expression of the 3A9 αβTCR ( Fig. 3d) . In this transfer, HEL peptide-pulsed plasma cells promoted the activation and proliferation of helper T cells, but the same dose of soluble HEL peptide did not. Thus, plasma cells probably gain physical access to naive helper T cells in vivo by migrating through lymphatics to the T cell zones of the draining lymph nodes. In this manner, pMHCII-expressing plasma cells can activate antigen-specific helper T cells in situ.
Plasma cells cannot induce the development of pre-GC T FH cells
Given the ability of switched plasma cells to act as antigen-presenting cells (APCs), it became important to compare and contrast this activity with that of conventional APCs. We found that the same number of switched plasma cells and CD11c + DCs pulsed with either peptide or protein antigen induced similar activation and proliferation in naive antigen-specific helper T cells ( Fig. 4a and Supplementary Fig. 7 ). We obtained similar results with two antigen systems (PCC and HEL) using different naive antigen-specific helper T cell populations ( Supplementary Fig. 8 ). Even substantially decreasing the antigen dose or the ratio of APC to helper T cell resulted in very little difference between the various types of APC ( Supplementary Fig. 9 ). Furthermore, analysis with activated antigen-specific helper T cells purified by flow cytometry for quantitative PCR after culture ( Supplementary Fig. 10 ) indicated that both types of APC induced robust and equivalent expression of mRNA ( Fig. 4b ) and protein ( Supplementary Fig. 11 ) for a series of known helper T cell-derived cytokines. However, in contrast, antigen-pulsed DCs induced high expression of IL-21 and Bcl-6 in activated helper T cells that was notably absent from the helper T cells in antigen-pulsed plasma cell cultures ( Fig. 4c) . Switched plasma cells uniquely induced Blimp-1, the transcriptional repressor of Bcl-6 and the T FH program. Thus, unlike DCs, switched plasma cells were unable to drive naive antigen-specific helper T cells toward the T FH fate in vitro.
Plasma cells decrease IL-21 and Bcl-6 in T FH cells
Antigen-specific T FH cells are required for the generation of isotypeswitched plasma cells in vivo. Thus, we considered it unlikely that naive helper T cells would be the main target of the APC activity of switched plasma cells in vivo. Therefore, we assessed whether antigen-primed plasma cells had an effect on the development or A r t i c l e s function of previously differentiated antigen-specific T FH cells. For this, we established primary helper T cell cultures with DCs and protein to induce T FH cells (as described above) and then subsequently divided the activated antigen-specific helper T cells across secondary cultures with isotype-switched plasma cells or CD11c + DCs, with or without antigen. CD11c + DCs supported the further accumulation of antigen-specific helper T cells regardless of antigen addition (Fig. 5a) . In contrast, plasma cells supported no further accumulation of helper T cells in the absence of antigen and supported the accumulation of significantly fewer helper T cells in the presence of antigen (Fig. 5a) . The antigen-dependent decrease occurred without changes in the abundance of mRNA for the antiapoptotic factors Bcl-2 and Bcl-X L or the apoptosis promoters Bax and Bak in the helper T cells ( Supplementary Fig. 12a ), which suggested no substantial changes via apoptosis in the culture. Thus, in contrast to their effect on the activation of naive helper T cells, switched plasma cells had a broad negative effect on previously activated effector helper T cells.
Although IL-21 is produced by many effector helper T cell subtypes 8 , it has been a useful indicator of selective T FH differentiation in vitro [20] [21] [22] [23] . Notably, we found an antigen-dependent decrease in IL-21 controlled by switched plasma cells ( Fig. 5b) . This functional deviation was selective for IL-21 without an effect on the production of other cytokines such as tumor necrosis factor or IL-10 ( Supplementary Fig. 12b ), which demonstrated antigen-specific downregulation of a major T FH cell function. Furthermore, Bcl-6 is a principal inducer of the T FH developmental program in vivo and in vitro [19] [20] [21] . In the secondary cultures, plasma cells resulted in significantly lower Bcl-6 expression in the antigen-specific helper T cells in an antigen-specific manner (Fig. 5b) . We extended those results to in vivo antigen-activated 5C.C7 αβTCR-transgenic helper T cells that produced demonstrable amounts of IL-21 after priming with antigen. In 24 h of short-term coculture, switched plasma cells resulted in lower expression of IL-21 and Bcl-6 in the helper T cells, in contrast to coculture with antigen-pulsed CD11c + DCs (Fig. 5c ). This effect was selective, as IL-4 and the transcription factor GATA-3 were unaffected and expression of the transcription factor T-bet was similarly affected by DC and plasma cell presentation (Supplementary Fig. 12c ). Those trends were recapitulated with nontransgenic polyclonal antigen-specific helper T cells positive for the TCR α-chain variable region 11 and β-chain variable region 3 (V α 11 + V β 3 + ) at day 7 after priming ( Fig. 5d and Supplementary Fig. 12d ). Therefore, antigen-specific plasma cells negatively regulate the function and developmental programming of antigen-specific T FH cells in vitro.
T FH cells accumulate in the absence of plasma cells
To understand the role of plasma cell presentation in vivo, we immunized C56BL/6 mice conditionally lacking Blimp-1 in the B cell compartment (called 'Blimp-1-cKO mice' here) with NP-KLH. An antigen-specific primary and memory B cell response develops in these mice without antibody-secreting cells from all stages of the immune response 30 . Notably, the primary GC reaction was also significantly larger in these mice, for reasons that remain unresolved 30 (P < 0.05; Supplementary Fig. 13a ). We quantified CXCR5 + PD-1 + T FH cells in the activated CD44 hi CD62L lo ICOS hi subset of CD4 + T cells that accumulated after primary immunization ( Fig. 6a and Supplementary Fig. 13b ). In the absence of plasma cells, CXCR5 + PD-1 + T FH cells accumulated to significantly greater numbers in the draining lymph nodes and spleen at all time points tested (days 9, 11 and 15; P < 0.05). In the T FH compartment, the brightest T FH cells (CXCR5 ++ PD-1 ++ ) were significantly greater in abundance at day 11 in the absence of plasma cells (P < 0.01), which suggested 'preferential' accumulation of GC T FH cells in these mice.
After local development in the GC, high-affinity post-GC plasma cells migrate to distal tissues that favor longevity and/or function of the secreting compartment. In the absence of plasma cells, CXCR5 + PD-1 + T FH cells accumulated to significantly greater numbers in the mesenteric lymph nodes, consistent with the loss of a local regulatory function for plasma cells in this region (P < 0.05; Supplementary Fig. 13c ). More CXCR5 − PD-1 + cells accumulated in the CD44 hi CD62L lo compartment of CD4 + helper T cells in the bone marrow without plasma cells (Supplementary Fig. 13d ). No change occurred in the Ly6C + memory CD4 + helper T cell compartment, which suggested a selective effect on PD-1 + helper T cells in this typically plasma cell-rich environment. These data suggested an additional function for plasma cells in favored survival niches and perhaps for extended periods after initial development in local GC environments.
Next we attempted to reverse the accumulation of T FH cells in the immunized Blimp-1-cKO mice at day 11. We transferred unfractionated lymph node and spleen cells from C57BL/6 mice 4 d after secondary immunization with the same antigen-adjuvant combination. Transferring this source of antigen-specific plasma cells restored T FH cell numbers in the spleen of immunized Blimp-1-cKO mice without affecting cell numbers in littermate controls ( Fig. 6b ) and decreased the greater T FH cell numbers in the lymph nodes to the numbers in littermate controls (Supplementary Fig. 14a) . At day 7 after priming, most antigen-specific helper T cells were in the follicular B cell areas but not in the GCs. At this early time point, there were significantly more CXCR5 + PD-1 + T FH cells in both the spleen and lymph nodes of Blimp-1-cKO mice (P < 0.05; Fig. 6c and Supplementary Fig. 14b,c) . Thus, in the absence of the development of plasma cells, the accumulation of greater numbers of T FH cells is consistent with the loss of a plasma cell-controlled local negative regulatory loop in vivo.
Plasma cells negatively affect T FH cells in vivo
When we assessed cells in situ after immunization of mice with PCC, we found large numbers of IgD − CD138 + plasma cells interspersed with T cells outside GCs at T cell-B cell borders and throughout T cell zones and the medullary regions ( Fig. 7a-e ). Furthermore, we found evidence of colocalization of CD138 + plasma cells with V β 3 + T cells that included the dominant antigen-specific responder helper T cell compartment 7, 8 , with evidence of cell contact at multiple points between V β 3 + T cells and CD138 + plasma cells at the T cell-B cell regions of these lymph nodes ( Fig. 7f-h) . Adoptive transfer of plasma cells pulsed with moth cytochrome c (MCC) peptide 2 d before the peak of the local antigen-specific T FH response induced selectively lower expression of Bcl-6 and IL-21 and not of IL-4 or GATA-3 ( Fig. 7i) , as assessed on a per-cell basis in purified CD44 hi CD62L lo CXCR5 + V α 11 + V β 3 + T FH cells as described 7, 8 .
There was no influence on the splenic T FH cell response in the lymphoid tissues that did not directly drain the site of adoptive transfer A r t i c l e s ( Supplementary Fig. 15 ). Thus, excessive numbers of plasma cells can negatively affect the local T FH program in antigen-responsive T FH cells in vivo.
DISCUSSION
Our findings challenge the existing paradigm that plasma cells are specialized only for antibody secretion. We have demonstrated that plasma cells participated in the cognate regulation of ongoing adaptive immunity. Isotype-switched plasma cells processed and presented antigen in vivo and functioned as highly competent APCs for naive helper T cells. However, we propose that antigen-specific plasma cells act at a later phase in the developing immune response to negatively regulate antigen-specific T FH cell function. The effect of negative regulation may extend into the GC reaction with an influence on distal immune-response sites and plasma cell-survival niches such as the bone marrow. We propose that there is an additional layer of negative regulation during adaptive immunity that senses the production of antigen-specific plasma cells to refine the ongoing development of high-affinity B cell memory.
Plasma cells are clearly specialized to secrete antigen-specific antibody. Blimp-1 orchestrates the development of plasma cells by repressing existing B cell programs (AID, Bcl-6 and Pax5), blocking cell cycle entry (c-Myc and E2f1) and initiating substantial changes in the secretory apparatus (J-chain) and unfolded protein response (XBP-1) 31 . In our study here, we have provided evidence of the maintenance of proteins associated with MHCII antigen processing and presentation, despite a low abundance of mRNA. How the MHCII machinery is maintained in the presence of low mRNA abundance and beyond the acute phase of the initial primary response remains unclear 39, 40 . Long-term protein stability is possible, but it is more likely that the small amount of mRNA is sufficient for the production of protein in plasma cells highly specialized for protein secretion 31 . There have been reports of MHCII and costimulatory molecules on plasma cells 41, 42 and transformed myelomas 43 . However, the ability of plasma cells to function as competent APCs was unexpected.
Post-mitotic cells that are highly specialized for secretion still need to sense and respond to environmental cues to exert effective regulatory function in vivo. We have provided evidence here of continued expression of BCRs on newly formed and long-lived plasma cells. The T FH compartment is already subspecialized for cognate pairing with antigen-experienced B cells [3] [4] [5] 44 . Multiple costimulatory and adhesion molecule pairs are expressed by these two cell types to create strong interactions of long duration after cognate contact 17, 18 . First, contact between T FH cells and B cells leads to higher expression of IL-21 and Bcl-6 (refs. [10] [11] [12] . There is also evidence of cognate contact between GC T FH cells and GC B cells by real-time imaging 45 and the sorting of T FH cell-GC B cell conjugates 46 . However, the developmental consequences of these cognate interactions for the GC T FH cells remain unclear. IL-21 production by T FH cells is central to affinity maturation, GC persistence, function and B cell fate determination 10, 11 . In our study here, we have demonstrated the ability of plasma cells to dampen the production of IL-21 by effector T FH cells in a negative feedback loop. We propose that these actions constitute an acute regulatory activity to contract T FH cell function, thereby constraining ongoing B cell immunity. Furthermore, given the evidence of continued expression of BCRs and MHCII presentation machinery in long-lived plasma cells, we speculate that there is an additional role for these interactions in the long-term survival of plasma cells.
Commitment to the plasma cell fate requires contact with T FH cells. In the spleen, non-GC plasma cells first appear in T cell areas and then migrate out through the bridging channels into the red pulp 1,2 . In the lymph nodes, plasma cells can accumulate at the T cell-B cell borders and the medullary cords 47 . Post-GC plasma cell commitment is also considered to be dependent on GC T FH cell signals. Evidence of PD-1 involvement 13 , a direct role for IL- 21 (refs. 10,11) and expression of Blimp-1 in the GC itself 48 further supports this position. Under normal physiological conditions, it is difficult to see the differentiation of plasma cells in the GC compartment. However, in the absence of the chemokine EBI-2, some GC B cells are unable to leave the GC and produce more discernible compartments of putative plasma cells in situ 49 . The rapid production of plasma cells after antigen rechallenge is dependent on CD4 + T FH cells; however, the distribution of memory response plasma cells in lymph nodes has not been well characterized. Nevertheless, these trends indicate that plasma cells or their immediate precursors reside in the same microenvironments as T FH subtypes to enable their selective control of the T FH program in vivo.
The finding of more T FH cells in the absence of plasma cells provides support for the idea of the existence of this negative regulatory loop in vivo. There were greater numbers of all CXCR5 + PD-1 + T FH cells in these mice at many time points after antigen priming. The GC T FH cell compartment has the highest expression of PD-1 and CXCR5 (ref. 5) , and these cells accumulate to greater numbers in the absence of plasma cells in vivo. It has also been suggested that these cells have the highest expression of ICOS and of GL-7 (ref. 50) , as a GC subset-specific marker. Although B cell memory develops in the absence of plasma cells 30 , its capacity for longterm immunoprotection is limited in the absence of plasma cells. The Blimp-1-cKO mice are also devoid of secreted antibodies that may influence the contraction of adaptive immunity. However, in the absence of the FcγR Fc receptor for IgG on helper T cells, these effects probably do not directly influence the T FH program. Furthermore, a greater number of GC T FH cells correlates with dysregulated GC selection and autoantibody production 5 . Thus, in the absence of plasma cells, we would predict that a greater number of GC T FH cells results in more IL-21 production that could alter normal GC physiology and the development and function of memory B cells.
Our studies of the mechanism of negative regulation by plasma cells indicate a requirement for antigen to dampen antigen-specific T FH cell activity. Our in vitro studies indicated that cognate contact is necessary but did not report on the effector mechanism. PD-1 expression by T FH cells and PD-L2 expression on GC B cells have been shown to have a role in regulating selection in the GC and the number of long-lived plasma cells 13 . IL-21 itself has an important role in these dynamic activities and the generation of high-affinity memory B cells 10, 11 . Thus, after cognate contact, the delivery of secondary modifying signals may be cell associated and secreted. It is also plausible that different sets of GC T FH cells may affect different types of GC B cells. For example, the pairing of IL-4-secreting GC T FH cells with IgG1-expressing GC B cells 46 has introduced the possibility of T FH cell-B cell subset dedication. Similarly, the rules that govern antigen-specific regulation by plasma cells in vivo focus on specific cognate TCR-pMHCII interactions and may be subsequently modified by cell-associated and secreted molecular determinants of cell fate.
Under the normal dynamics of protein vaccination, constraining T FH cell numbers and lower IL-21 production may progressively increase competitive pressure critical for GC survival signals. Thus, we predict that the negative regulation of GC T FH cell function could enhance affinity maturation in the GC and promote memory B cells with higher overall affinities. This cellular 'product-toinducer' negative regulatory mechanism may also increase GC selection thresholds to help guard against potential self-reactivity in the GC. In the memory response, a negative regulatory loop would act as an antigen-specific plasma cell-sensing mechanism to limit the accelerated and explosive production of plasma cells that accompanies antigen rechallenge. We suggest that sensing the antigen-specific plasma cell product of the T FH cell regulatory pathway may also provide an efficient means of constraining autoreactivity and fine tuning ongoing antigen-specific B cell immunity in vivo.
The cognate control of B cells by T FH cells is an important and active area of research. We believe that the effect of B cell-controlled antigen presentation on the development and function of antigenspecific T FH cells remains poorly understood. This cascade of bidirectional regulation is central to effective adaptive immunity and regulates the emergence of antigen-specific immune memory. The previously unknown mechanism of antigen-specific plasma cell control that we have identified here is one facet of this largely unexplored cognate immune regulatory mechanism.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/. nature immunology doi:10.1038/ni.1954
ONLINE METHODS
Mice. C57BL/6, B10.BR, B10.BR-Thy1.1, 5C.C7 αβTCR-transgenic and 3A9 αβTCR-transgenic mice were maintained in specific pathogen-free conditions at The Scripps Research Institute. Mice with loxP-flanked Prdm1 alleles (encoding Blimp-1) excised by Cre recombinase expressed from a CD19 promoter were obtained from K. Calame and backcrossed nine generations onto the C57BL/6 strain and were maintained in specific pathogen-free conditions at The Scripps Research Institute. The Scripps Research Institutional Animal Care and Use Committee approved all experiments.
Immunization. Mice were immunized subcutaneously with 400 μg NP-KLH, PCC protein (Sigma) or HEL protein (Sigma) in monophosphoryl lipid Abased adjuvant 7 for the primary immunization. Secondary challenge was done 6 weeks or more after primary immunization and was either identical to the primary immunization or 40 μg soluble HEL in PBS.
Flow cytometry. Cell suspensions were made as described 7 . For surface staining, 4 × 10 8 cells per ml were incubated for 45 min at 4 °C with the following labeled monoclonal antibodies conjugated in the laboratory: anti-CD3 (145.2C11), anti-CD8 (53-6.7), anti-CD11c (HL3), anti-CD62L (MEL-14), anti-CD80 (16-10A1), anti-CD86 (GL1), anti-CD138 (281-2), anti-B220 (RA3-6B2), anti-IgM (II/41), anti-GL7 (GL7), anti-Ly6C (AL21), anti-CXCR5 (2G8) and anti-I-A k (10-3.6; all from BD Pharmingen); anti-CD4 (GK1.5), anti-CD11c (N418), anti-CD278 (ICOS; C398.4A), anti-Gr-1 (RB6-8C5) and anti-I-A b (KH74; all from BioLegend); anti-CD19 (6D5), anti-CD38 (90), anti-CD44 (IM7), anti-PD1 (J43) and anti-F4/80 (BM8; all from eBioscience); anti-CD11b (M1/70.15), anti-V β 3 (KJ25) and anti-IgD (11.26 ; all produced in-house); antibody to HEL amino acids 48-61 in I-A k (Aw3.18), NP (4-hydroxy 3-nitrophenylacetyl; Biosearch); and anti-HEL (Sigma). For the double-biotinylated monoclonal antibody strategy, crossreactivity was diminished by blockade with excess free biotin (Perbio).
For intracellular staining, surface-labeled cells were made permeable and fixed with Cytofix/Cytoperm (BD Pharmingen), then labeled with the following monoclonal antibodies: anti-IgG1 (A85-1), anti-IgG2a (R19-15), anti-IgG2b (R12-3), anti-IgG3 (R40-82), anti-IgA (R5-140), anti-IgM (R6-60.2) and anti-CD74 (In-1; all from BD Pharmingen); anti-H2-M (2C3A) and anti-H2-O (Ob1; both from L. Denzin); and antibody to I-A b -CLIP (15G4; from A. Rudensky). Samples were analyzed on FACSVantage or FACSAria III (BD Biosciences) and data were processed with FlowJo software (TreeStar). Exclusion criteria (Dump) included anti-CD4, anti-CD8, anti-Gr-1 and anti-F4/80 (for plasma cells and naive B cells); anti-B220, anti-CD8 and anti-CD11b (for CD4 + helper T cells); and anti-CD19 and anti-CD3 (for CD11c + DCs).
BrdU analysis.
Mice received a single intraperitoneal injection of 800 μg BrdU (5-bromodeoxyuridine; BD Biosciences) and cells were prepared with a BrdU flow kit (BD Pharmingen).
Antigen-presentation assays. After being primed in vivo with PCC or adjuvant only, plasma cells were sorted as PI − Dump − IgD − CD138 + IgM − from lymph nodes 10 d after immunization and were cultured for 4 d at a density of 5 × 10 3 cells per well with 5 × 10 4 naive PCC-specific helper T cells (PI − Dump − CD4 + CD44 − CD62L + ) sorted from 5C.C7 αβTCR-transgenic mice and labeled for 5 min at 24 °C with 5 μM CFSE (carboxyfluorescein diacetate succinimidyl ester; Molecular Probes). For in vivo antigen presentation, 9.0 × 10 5 isotype-switched plasma cells were sorted from lymph nodes 5 d after immunization with adjuvant only, then were pulsed for 1 h at 24 °C with 10 μM HEL peptide and transferred subcutaneously into B10.BR mice that had previously received the equivalent of 5 × 10 6 CFSE-labeled helper T cells from donor 3A9 αβTCR-transgenic spleens. T cell proliferation was analyzed 3 d later. For assay of in vitro antigen presentation to naive helper T cells, 5 × 10 4 CFSE-labeled naive PCC-specific helper T cells were cultured with 5 × 10 3 plasma cells or DCs (PI − Dump − CD11c + ), sorted from lymph nodes 5 d after immunization with adjuvant only, and with 10 μM MCC peptide (amino acids 88-103; Anaspec) or 10 μM PCC protein.
For analysis of antigen presentation to activated T cells, PCC-specific naive T cells were activated either in vitro for 4 d with DCs in the presence of PCC or in vivo for 7 d after transfer of 5 × 10 5 5C.C7 αβTCR-transgenic helper T cells into B10.BR mice simultaneously immunized with PCC-adjuvant or sorted antigen-activated V α 11 + V β 3 + helper T cells from B10.BR mice without transfer as described 8 . Subsequently, activated helper T cells (PI − Dump − CD4 + CD44 hi CD62L lo ) were sorted and cultured for 3 d or 24 h at a ratio of 10:1 with plasma cells or DCs with or without PCC. All cultures were done in RPMI medium supplemented with 10% (vol/vol) FCS, 1× penicillin-streptomycin-l-glutamine and 50 μM 2-mercaptoethanol (Invitrogen). For adoptive transfer into Blimp-1-cKO mice and littermate control mice, 1.0 × 10 8 unfractionated spleen and lymph node mixtures from C57BL/6 mice on day 4 after secondary immunization with NP-KLH in Ribi were distributed evenly and injected intraperitoneally and into the base of the tail of recipient mice at day 9 after initial priming of both groups of mice. For assay of antigen presentation to antigen-specific T FH cells in vivo, 3.0 × 10 5 isotype-switched plasma cells were sorted from lymph nodes 5 d after immunization with adjuvant only, then were pulsed for 1 h at 25 °C with 10 μM MCC peptide and were transferred subcutaneously into B10.BR mice that had been immunized 5 d earlier with PCC in adjuvant. T FH cells were sorted 2 d later for gene-expression analysis.
Enzyme-linked immunospot assay. Plasma cell function was measured as described 14 with NP-BSA or IgM and IgG antibody to mouse (Southern Biotechnology Associates).
Estimation of mRNA by quantitative RT-PCR.
For quantitative PCR ex vivo immediately after isolation, 1 × 10 6 helper T cells (PI − Dump − CD4 + ), DCs (PI − Dump − CD11c + ), naive B cells (PI − Dump − B220 + IgD + IgM + ) or isotypeswitched plasma cells (PI − Dump − IgD − CD138 + IgM − ) were sorted either from lymph nodes of HEL-adjuvant-immunized B10.BR mice 1 d after immunization (T cells and DCs) or from spleens of HEL-adjuvant-immunized B10.BR mice 5 d after secondary immunization (B cells and PCs). For gene-expression analysis after antigen-presentation assay, activated helper T cells (PI − Dump − CD4 + CD44 hi CFSE lo ) were sorted from individual wells after culture. For gene-expression analysis after transfer of plasma cells in vivo, antigen-specific T FH cells (PI − Dump − CD4 + V α 11 + V β 3 + CD44 hi CD62L lo CXCR5 + ) were sorted from B10.BR mice 7 d after immunization with PCC. All samples were sorted for RNA extraction, cDNA synthesis and quantitative PCR as described 8 . The mRNA purified after in vitro assay of antigen presentation to naive helper T cells (Fig. 4b,c ) was amplified by two rounds of in vitro transcription as described 8 Table 1 ). Results were analyzed with Rotor-Gene 6.0 software or StepOne software version 2.0.
(primers, Supplementary
Confocal microscopy.
Inguinal lymph nodes were embedded in Tissue-Tek optimum cutting temperature compound (Sakura) and were snap frozen on dry ice. Sections 6-8 μm in thickness were fixed in cold acetone and were stained in PBS containing 10% (vol/vol) FCS and 0.1% (vol/vol) sodium azide with the following labeled antibodies: anti-IgD (11.26) and anti-V β 3 (KJ25; both produced and labeled in the laboratory); anti-CD90.2 (53-2.1) and anti-CD138 (281.2; both from BD Biosciences); IgG antibody to rat (Vector); and rhodamin red-streptavidin (Invitrogen). Confocal images were analyzed with an Olympus Fluoview 500 confocal microscope. It has been called to our attention that in a series of studies on the development of follicular helper T cells (T FH cells), the primers we used to amplify Bcl6 were specific for Bcl6b, not Bcl6. We have now traced back the results and have redone experiments that demonstrate that both Bcl6 and Bcl6b are modified in the same way and to a similar extent in antigen-specific and non-antigen-specific T FH cells induced both in vivo and in vitro.
In the original studies we inadvertently mixed up primers specific for Bcl6b (but not for Bcl6) with those specific for Bcl6. After closer inspection, we found that this error was made when the wrong set of primers was ordered and labeled "Bcl6 #2" in our laboratory but the primers were in fact specific for Bcl6b. We used both sets of primers in the original studies of gene expression on antigen-specific T FH cells analyzed immediately after isolation ( Fig. 3f in Nat. Immunol. 10, 375-384 (2009), and Addendum Fig. 1) . Hence, the expression of both Bcl6 and Bcl6b seemed to be three-to fourfold higher in pigeon cytochrome c (PCC)-specific T FH cells than in naive CD4 + helper T cells.
As these genes are structurally related, we were concerned that the primers for Bcl6b may have sufficiently cross-reacted with Bcl6 and perhaps amplified the latter gene in T cells. Thus, we sorted antigen-specific T FH cells immediately after isolation and amplified random hexamer-primed cDNA with both sets of primers (Addendum Fig. 2 ). Both gene products were amplified and produced PCR products of different sizes (the predicted sizes for the different gene products). We then sequenced these products to demonstrate they belonged to the different genes as presented. Thus, both primers amplified the expected PCR products in both naive helper T cells and antigen-specific T FH cells.
To explore this issue further, we sorted non-antigen-specific T FH cells on the basis of cell surface phenotype and amplified DNA from these cells by RT-PCR without further treatment (Addendum Fig. 3) . These experiments also showed that both Bcl6 and Bcl6b had similar basal expression in naive helper T cells and a similar change of expression in CXCR5 + T FH cells.
In our more recent study on antigen presentation by plasma cells (Nat. Immunol. 11, 1110-1118 (2010)), we reported that plasma cells negatively regulate the T FH program in vitro and in vivo. Our conclusions were based on expression of the genes encoding interleukin 21 (IL-21) and Bcl-6, as measured by reverse transcription and quantitative PCR. The original primer mix-up continued in the early phase of these studies. However, the error was sporadic and these more recent studies reported on Bcl6 and not Bcl6b, as outlined below (Addendum Table 1 ).
Hence, we concluded that antigen presentation by plasma cells inhibits the expression of mRNA for IL-21 and Bcl-6 by in vivo-derived, endogenous, antigen-specific T FH cells (Fig. 5d, second panel, in Nat. Immunol. 11, 1110-1118 (2010)). Furthermore, the adoptive transfer of antigen-pulsed plasma cells significantly inhibited the expression of mRNA for both IL-21 and Bcl-6 on antigen-specific T FH cells (Fig. 7i, in Nat. Immunol. 11, 1110-1118 (2010)) without affecting the expression of mRNA for IL-4 or the transcription factor GATA-3 in vivo. Therefore, this provided evidence of antigen-specific negative regulation of the T FH program by plasma cells in vivo.
We have also repeated the in vitro experiments using dendritic cells (DCs) or plasma cells as antigen-presenting cells to evaluate the expression of Bcl6 and Bcl6b after in vitro induction of T FH cell activity (Addendum Fig. 4) . These studies demonstrated equivalent induction of both Bcl6 and Bcl6b in vitro with DCs as antigen-presenting cells and naive helper T cells with transgenic expression of the 5C.C7 ab T cell antigen receptor (abTCR) as antigen-specific helper T cells in these cultures. Consistent with the overall conclusions of our earlier study (Nat. Immunol. 11, 1110−1118 (2010)) plasma cells with antigen did not induce Bcl6 or Bcl6b in 5C.C7 abTCR-transgenic helper T cells in vitro.
We did these new experiments without secondary in vitro transcription or specific synthesis of target cDNA and preamplification by PCR to evaluate the extent of signal to be expected for Bcl6 after in vitro activation of T FH cells. The tenfold induction of both Bcl6 and Bcl6b in these studies is more in line with the expected results and the results of other studies using standard culturing conditions to induce T FH cell activity. These data are also more in line with the expression of Bcl6 and Bcl6b on antigen-specific T FH cells derived in vivo we have reported in all our studies. We believe that the starting cell population, in particular the primary culture stimulus, atypical secondary culture conditions and secondary amplification of the assay all contributed to the more enhanced signals we reported before for Bcl6b (Fig. 5b,c in Nat. Immunol. 11, 1110−1118 (2010)).
In conclusion, we mixed up primers for Bcl6 amplification and in parts of our published work inadvertently reported on Bcl6b, not Bcl6. Bcl6b is a distinct gene but remains a structurally and functionally related member of the Bcl6 gene family. We have now been able to revisit this issue and have demonstrated that both Bcl6 and Bcl6b seemed to be coexpressed to a similar extent in naive helper T cells. Both gene products were similarly enhanced in T FH cells that emerged in vivo or were derived in vitro. Furthermore, both genes seemed to be inhibited similarly by antigen presentation by plasma cells. Hence, we believe that this addendum will rectify the mistake made in the initial studies and clarify the coexpression of Bcl6 and Bcl6b in antigen-specific T FH cells. Induction of Bcl6 or Bcl6b in T FH cells selectively by dC antigen presentation and inhibition of Bcl6 by PC antigen presentation, assessed by two rounds of in vitro amplification (IVT) of Rna with a Messengeramp II aRna amplification kit (ambion), similar to what is done before microarray analysis, followed by the generation of cdna from 10 mg amplified Rna as the starting material for SYBR Green-based quantitative PCR analysis; by specific target amplification (STa) with specific primers to generate cdna, followed by 14 cycles of PCR preamplification and dilution of the product 1:5 for use as the starting material for SYBR Green-based quantitative PCR analysis; or the melting curve (T m ) peak signal after SYBR Green-based quantitative PCR analysis. Addendum Figure 1 Upregulation of both Bcl6 and Bcl6b in antigenspecific T FH cells analyzed immediately after isolation. Quantitative PCR analysis of Bcl6 mRna and Bcl6b mRna in naive helper T cells (V a 11 + V b 3 + Cd44 lo Cd62L hi ) or PCC-specific T FH cells (PI -B220 -Cd11b -Cd8 -V a 11 + V b 3 + Cd44 hi Cd62L lo CXCR5 hi ) sorted from draining lymph nodes on day 7 after subcutaneous priming with PCC in Ribi adjuvant (2 × 10 3 cells), followed by cdna synthesis and amplification with Platinum SYBR Green (details as for Figs. 1-3 in the original study (Nat. Immunol. 10, 375−384 (2009))); results are presented in arbitrary units (aU) relative to the expression of b 2 -microglobulin mRna, set as 1. Other antigen-specific helper T cell subsets are sorted on the basis of differences in the expression of Cd62L and CXCR5 as described in detail in the original study (Nat. Immunol. 10, 375−384 (2009)). a d d e n d a
